On Thursday, Citi updated its stance on Mirion Technologies (NYSE:MIR) stock, raising the price target from $17.00 to $18.00 and maintaining a Buy rating. The adjustment follows Mirion's third-quarter financial results and the company's increased organic growth projections for 2024.
Mirion Technologies, known for its nuclear measurement and analysis services, has raised its organic growth forecast for 2024, signaling strong market positions and robust demand in nuclear-related end-markets. The company has also identified potential new order opportunities worth between $300 million and $400 million by the end of 2025, further indicating broad-based demand growth.
During the third-quarter earnings call, Mirion provided additional details concerning the de-booking of a Turkey order due to a contractual dispute. The company expressed optimism about the possibility of regaining this business, a development that Citi views as a positive sign.
The third-quarter results not only reflected a favorable demand environment but also demonstrated the impact of Mirion's internal improvement initiatives. The company reported an approximate 370 basis point year-over-year increase in adjusted EBITDA margin within its Technologies segment, outperforming the pre-print estimate of 25.5% with actual results of 26.3%.
Citi anticipates further insights into Mirion's market momentum, especially in core commercial nuclear markets, at the upcoming Investor Day scheduled for December 3, 2024.
In other recent news, Mirion Technologies reported an 8% increase in Q3 2024 revenue, reaching $207 million, with an adjusted EPS of $0.08. Despite a 30% drop in third-quarter orders year-over-year, the company saw significant growth in the nuclear power and cancer care markets, driven by deals with major tech companies and advancements in radiopharmaceutical therapies. Goldman Sachs upgraded its target for Mirion Technologies to $16, maintaining a Buy rating on the stock, reflecting a positive view on the growing momentum in nuclear new builds.
Mirion Technologies secured two major contracts for the Sizewell C project, contributing to the $30 million in orders shifted from Q2 to Q3. The company indicated an active bid pipeline of approximately $300-$400 million for large projects, expected to convert into orders by the end of 2025. However, the company faced a setback with the de-booking of half of a Turkish new build award valued at $21 million due to contractual disputes.
Mirion Technologies reaffirmed its full-year 2024 adjusted EBITDA guidance of $195 million to $205 million and its EPS forecast of $0.37 to $0.42. The company's backlog currently stands at $815 million, up 2% from last year, indicating a robust pipeline, particularly in the nuclear sector. These are among the recent developments at Mirion Technologies.
InvestingPro Insights
Mirion Technologies' recent performance and positive outlook are reflected in the latest InvestingPro data and tips. The company's market cap stands at $3.15 billion, with a strong revenue of $836.9 million over the last twelve months as of Q3 2024. This aligns with Citi's optimistic view on the company's growth prospects.
InvestingPro Tips highlight that Mirion's net income is expected to grow this year, and analysts predict the company will be profitable this year. These projections support Citi's bullish stance and the raised price target. Additionally, the company's liquid assets exceed short-term obligations, indicating a solid financial position to support its growth initiatives.
The stock has shown impressive performance, with a 112.84% return over the past year and a 33.24% return in the last month. This strong momentum is consistent with Mirion's raised organic growth forecast and the potential new order opportunities mentioned in the earnings call.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Mirion Technologies, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.